Rhythm Pharmaceuticals (RYTM) to Offer $150M in Common Stock

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced a proposed public offering of $150 million of shares of its common stock. All shares in the offering will be offered by Rhythm. In addition, Rhythm intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of common stock at the public offering price, less the underwriting discount and commission.

Morgan Stanley, BofA Securities, Cowen and Stifel will act as the joint book-running managers for the proposed offering. Canaccord will act as lead manager for the proposed offering. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed.

You May Also Be Interested In

• Silence Therapeutics closes $201M public offering of ADSs
• HeartFlow (HTFL) PT Raised to $45 at Stifel as Plaque Business Revenue Ramps
• Zentalis Pharmaceuticals prices $80.5M public stock offering